The impact of wild-type reversion on transmitted resistance surveillance.
作者信息
Boettiger David C, Kiertiburanakul Sasisopin, Sungkanuparph Somnuek, Law Matthew G
机构信息
Kirby Institute for Infection and Immunity in Society, UNSW Australia, Sydney, New South Wales, Australia.
出版信息
Antivir Ther. 2014;19(7):719-22. doi: 10.3851/IMP2746. Epub 2014 Feb 17.
Abstract
摘要
相似文献
1
The impact of wild-type reversion on transmitted resistance surveillance.野生型回复对传播耐药性监测的影响。
Antivir Ther. 2014;19(7):719-22. doi: 10.3851/IMP2746. Epub 2014 Feb 17.
2
A fossil record of zidovudine resistance in transmitted isolates of HIV-1.HIV-1传播株中齐多夫定耐药性的化石记录。
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13485-7. doi: 10.1073/pnas.251559398.
3
Detection and significance of minority quasispecies of drug-resistant HIV-1.耐药性HIV-1少数准种的检测及其意义
J HIV Ther. 2006 Dec;11(4):74-81.
4
Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a Disconnect.传播的和获得性的1型艾滋病毒耐药性之间的相互作用：脱节的原因
J Infect Dis. 2015 Jul 1;212(1):5-7. doi: 10.1093/infdis/jiv008. Epub 2015 Jan 9.
5
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy.意大利北部一家大型教学医院新诊断的HIV-1感染患者中传播性耐药突变的流行情况。
J Med Virol. 2020 Aug;92(8):929-931. doi: 10.1002/jmv.25896. Epub 2020 Jun 3.
6
Sustained profile of transmitted drug resistance mutations for more than 10 years in an HIV type 1-infected patient.
AIDS Res Hum Retroviruses. 2011 Jan;27(1):41-5. doi: 10.1089/aid.2010.0104. Epub 2010 Oct 4.
7
Revisiting the concept of a genetic barrier to resistance.重新审视抗性遗传屏障的概念。
J HIV Ther. 2006 Dec;11(4):81-3.
8
Current insights into reverse transcriptase inhibitor-associated resistance.逆转录酶抑制剂相关耐药性的当前见解。
Antivir Ther. 2001;6 Suppl 2:11-9.
9
Update of the drug resistance mutations in HIV-1: Spring 2008.2008年春季HIV-1耐药性突变的更新情况。
Top HIV Med. 2008 Apr-May;16(1):62-8. doi: 10.1007/s11750-007-0034-z.
10
Antiretroviral Resistance Mutations (revised April 2001).抗逆转录病毒耐药性突变（2001年4月修订）
HIV Clin Trials. 2001 Jul-Aug;2(4):346-55. doi: 10.1310/8FXB-B0EK-D525-BVU3.
引用本文的文献
1
Added Value of Next Generation Sequencing in Characterizing the Evolution of HIV-1 Drug Resistance in Kenyan Youth.肯尼亚青年中 HIV-1 耐药性进化的下一代测序的附加价值。
Viruses. 2023 Jun 22;15(7):1416. doi: 10.3390/v15071416.
2
Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.赞比亚恩多拉接受抗逆转录病毒治疗（ART）的艾滋病病毒感染青少年和青年中艾滋病病毒耐药性的流行情况和特征。
PLoS One. 2020 Aug 17;15(8):e0236156. doi: 10.1371/journal.pone.0236156. eCollection 2020.
3
Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County.对圣克拉拉县一家县级艾滋病诊所新诊断出的、未接受过治疗的个体中传播的艾滋病毒耐药性进行监测。
Heliyon. 2019 Sep 11;5(9):e02411. doi: 10.1016/j.heliyon.2019.e02411. eCollection 2019 Sep.
4
Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S.亚洲四个城市（2007-2010 年）新感染 HIV 阳性个体中的传播药物耐药性- TASER-S。
AIDS Res Ther. 2015 Feb 13;12:3. doi: 10.1186/s12981-015-0043-1. eCollection 2015.
本文引用的文献
1
HIV-1 genetic variation and drug resistance development.HIV-1 基因变异与耐药性产生。
Expert Rev Anti Infect Ther. 2013 Nov;11(11):1159-78. doi: 10.1586/14787210.2013.844649.
2
Persistence of HIV-1 transmitted drug resistance mutations.HIV-1 传播耐药突变的持续存在。
J Infect Dis. 2013 Nov 1;208(9):1459-63. doi: 10.1093/infdis/jit345. Epub 2013 Jul 31.
3
Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients.亚洲患者次区域队列中近期和慢性HIV-1感染的原发性HIV-1耐药性比较
PLoS One. 2013 Jun 27;8(6):e62057. doi: 10.1371/journal.pone.0062057. Print 2013.
4
Differential persistence of transmitted HIV-1 drug resistance mutation classes.传播的 HIV-1 耐药突变类别的差异持久性。
J Infect Dis. 2011 Apr 15;203(8):1174-81. doi: 10.1093/infdis/jiq167.
5
Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.队列简介：PharmAccess非洲（PASER-M）和亚太地区治疗（TASER-M）监测研究，以评估撒哈拉以南非洲和亚太地区的耐药性——艾滋病毒耐药性。
Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. Epub 2010 Nov 10.
6
Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.慢性 HIV-1 感染、未经治疗的患者中 HIV-1 主要耐药突变 K65R、K103N 和 M184V 作为少数变异体的流行情况。
J Clin Virol. 2011 Feb;50(2):156-61. doi: 10.1016/j.jcv.2010.10.001. Epub 2010 Nov 4.
7
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.用于监测传播的HIV-1耐药性的耐药性突变：2009年更新
PLoS One. 2009;4(3):e4724. doi: 10.1371/journal.pone.0004724. Epub 2009 Mar 6.
8
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.在无拉米夫定情况下，多药耐药1型人类免疫缺陷病毒中M184V突变的体内适应性代价
J Virol. 2009 Feb;83(4):2038-43. doi: 10.1128/JVI.02154-08. Epub 2008 Nov 19.
9
10
Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation.HIV-1蛋白酶中G48E替代对复制适应性的影响：一项体外和计算机模拟评估。
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):255-62. doi: 10.1097/QAI.0b013e318174dca6.
Zotero 插件